

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

IGROV-1

RRID:CVCL_1304

Type: Cell Line

Proper Citation

RRID:CVCL_1304

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1304

Proper Citation: RRID:CVCL_1304

Description: Cell line IGROV-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian endometrioid adenocarcinoma

Defining Citation: [PMID:2041050](#), [PMID:3335022](#), [PMID:8564971](#), [PMID:9331090](#), [PMID:9443634](#), [PMID:9488600](#), [PMID:9636834](#), [PMID:10700174](#), [PMID:10817511](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:16319398](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22328975](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:23856246](#), [PMID:23913215](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32612269](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: IGROV-1

Synonyms: Igrov-1, IGROV 1, IGR-OV1, IGROV1, Igrov1, IGR.OV1, IGROV, OV1/P, OV1/p, OV1-P

Cross References: BTO:BTO_0002575, CLO:CLO_0006672, EFO:EFO_0005385, CLDB:cl2627, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:897, BioSample:SAMN03470926, BioSample:SAMN10988218, cancercellines:CVCL_1304, Cell_Model_Passport:SIDM00151, ChEMBL-Cells:ChEMBL3307502, ChEMBL-Targets:ChEMBL613984, CLS:305556, Cosmic:688100, Cosmic:875857, Cosmic:897430, Cosmic:905968, Cosmic:920360, Cosmic:947357, Cosmic:1044236, Cosmic:1092607, Cosmic:1093557, Cosmic:1102823, Cosmic:1175880, Cosmic:1305334, Cosmic:1312353, Cosmic:1707557, Cosmic:1709252, Cosmic:1998449, Cosmic:2464669, Cosmic-CLP:905968, DepMap:ACH-000966, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905968, GEO:GSE23440, GEO:GSE25191, GEO:GSM2127, GEO:GSM50218, GEO:GSM50281, GEO:GSM313715, GEO:GSM711720, GEO:GSM743472, GEO:GSM743496, GEO:GSM750827, GEO:GSM799361, GEO:GSM799424, GEO:GSM844567, GEO:GSM844568, GEO:GSM844569, GEO:GSM844570, GEO:GSM846360, GEO:GSM851919, GEO:GSM887160, GEO:GSM888232, GEO:GSM1153432, GEO:GSM1181284, GEO:GSM1181285, GEO:GSM1291142, GEO:GSM1374571, GEO:GSM1669930, GEO:GSM2124667, IARC_TP53:21072, IARC_TP53:21125, IARC_TP53:30209, LiGeA:CCLE_165, Lonza:175, Millipore:SCC203, NCI-DTP:IGR-OV1, PharmacDB:IGROV1_654_2019, PRIDE:PXD003539, PRIDE:PXD003668, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1304, PubChem_Cell_line:CVCL_1304, SKY/M-FISH/CGH:2739, Wikidata:Q54897382

ID: CVCL_1304

Record Creation Time: 20220427T220631+0000

Record Last Update: 20260829T234313+0000

Ratings and Alerts

No rating or validation information has been found for IGROV-1.

No alerts have been found for IGROV-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Dexheimer TS, et al. (2025) High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids. *SLAS discovery : advancing life sciences R & D*, 37, 100284.

Chelariu-Raicu A, et al. (2025) IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer. *Cancer research communications*, 5(3), 512.

Thomine C, et al. (2025) The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer. *Molecular oncology*.

Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR α -Targeted TOP1i-Loaded ADC, for the Treatment of FR α -Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5261.

Yeung CLS, et al. (2025) Identification of molecular markers and exploration of the oncogenic role of exomeres in hepatocellular carcinoma. *Cell reports*, 44(11), 116460.

Delafiori J, et al. (2025) HT SpaceM: A high-throughput and reproducible method for small-molecule single-cell metabolomics. *Cell*.

Vogl AM, et al. (2025) TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile. *Molecular cancer therapeutics*, 24(11), 1685.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Schoepf AM, et al. (2024) Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives. *Journal of medicinal chemistry*.

Rogmans C, et al. (2024) Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids. *Scientific reports*, 14(1), 26926.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Krushkal J, et al. (2024) Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors. *Epigenetics*, 19(1), 2309824.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. *Cell reports*, 43(4), 114041.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Wang X, et al. (2023) Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. *Nature*

protocols, 18(1), 265.

Jiang W, et al. (2023) A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. International journal of molecular sciences, 24(6).

Ghilardi C, et al. (2022) PGC1 α Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer research, 82(7), 1423.

Bose S, et al. (2022) G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment. Cell reports, 39(13), 111012.

Islam S, et al. (2022) Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis. International journal of cancer, 150(9), 1512.